Related Experiment Video

Updated: Jun 15, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Cyclin-dependent kinase inhibitors as anticancer drugs

Vladimír Krystof1, Stjepan Uldrijan

  • 1Laboratory of Growth Regulators, Palacký University & Institute of Experimental Botany AS CR, 78371 Olomouc, Czech Republic. vladimir.krystof@upol.cz

Current Drug Targets
|March 10, 2010
PubMed

Insights

New cyclin-dependent kinase (CDK) inhibitors show promise for cancer therapy by targeting transcription and promoting apoptosis. Research explores their mechanisms, anticancer activities, and potential resistance pathways.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Current cancer therapies face challenges including poor outcomes, side effects, and drug resistance.
  • Cyclin-dependent kinases (CDKs), particularly CDK7 and CDK9, are crucial for RNA polymerase II transcription and cell cycle regulation.
  • There is a significant need for novel, targeted cancer drugs.

Purpose of the Study:

  • To report on the preclinical development of CDK inhibitors and their anticancer effects.
  • To investigate the mechanisms of action for pan-specific CDK inhibitors like flavopiridol and roscovitine.
  • To discuss the links between CDK inhibition, cancer cell sensitization to apoptosis, p53 activation, and synergistic effects with DNA damaging agents.

Main Methods:

  • Preclinical development of CDK inhibitors.
  • Evaluation of anticancer activities.
  • Analysis of mechanisms of action, including effects on transcription, apoptosis, and p53 activation.
  • Exploration of synergistic effects with DNA damaging drugs.

Main Results:

  • Flavopiridol and roscovitine, pan-specific CDK inhibitors, have entered Phase II clinical trials.
  • CDK inhibitors demonstrate anticancer activities by inhibiting transcription and sensitizing cancer cells to apoptosis.
  • These inhibitors can activate p53 pathways and exhibit synergistic effects with DNA damaging agents.

Conclusions:

  • CDK inhibitors represent a promising new class of targeted cancer drugs.
  • Understanding their mechanisms, including transcription inhibition and apoptosis induction, is key to their therapeutic application.
  • Potential mechanisms of resistance to CDK inhibitors are discussed, drawing parallels with other kinase inhibitors.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.